Levels of soluble receptor for advanced glycation end products in acute ischemic stroke without a source of cardioembolism

Journal of Clinical Neurology (Korea)

Volumn 5, Issue 3, 2009, Pages 126-132

  Park, Hyun Young ^a   Yun, Kyeong Ho ^a   Park, Do Sim ^a  

^a Wonkwang University School of Medicine   (South Korea)

Author keywords

Diabetes; Hypercholesterolemia; Hypertension; Soluble receptor for advanced glycation end products; Stroke

Indexed keywords

EID: 79955529885     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2009.5.3.126     Document Type: Article

References (23)

1. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, et al. Survey of the distribution of a newly characterized receptor for ad- vanced glycation end products in tissues. Am J Pathol 1993;143: 1699-1712.
2. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995;270:25752-25761.
3. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced gly-cation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002;54:1615-1625.
4. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008;196:9-21.
5. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007;13:625-635.
6. Ma L, Carter RJ, Morton AJ, Nicholson LF. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ische-mic brain injury in rats. Brain Res 2003;966:167-174.
7. Zhai DX, Kong QF, Xu WS, Bai SS, Peng HS, Zhao K, et al. RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats. Neurosci Lett 2008;445:117-121.
8. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apoli-poprotein E-null mice. Circulation 2002;106:2827-2835.
9. Basta G, Sironi AM, Lazzerini G, del Turco S, Buzzigoli E, Caso-laro A, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628-4634.
10. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725-1729.
11. Santilli F, Bucciarelli L, Noto D, Cefalù AB, Davì V, Ferrante E, et al. Decreased plasma soluble RAGE in patients with hypercholeste-rolemia: effects of statins. Free Radic Biol Med 2007;43:1255-1262.
12. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterio-scler Thromb Vasc Biol 2005;25:1032-1037.
13. Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005;62:1734-1736.
14. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stro ke 1993;24:35-41.
15. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007;23:368-371.
16. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jin-nouchi Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed en-dothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005;70:137-141.
17. Yamagishi S, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 2007;27: e32; author reply e33-e34.
18. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Ar-terioscler Thromb Vasc Biol 2005;25:2587-2593.
19. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, et al. Decreased endogenous secretory advanced glyca-tion end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005;28: 2716-2721.
20. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 2007;190:22-23.
21. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 2008;5:190-197.
22. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardio-vasc Diabetol 2007;6:9.
23. Jung KH, Roh JK. Circulating endothelial progenitor cells in cere-brovascular disease. J Clin Neurol 2008;4:139-147.